Featured Research

from universities, journals, and other organizations

FDA Approves Drug For Use In Cataract Surgery

Date:
December 23, 2004
Source:
U.S. Food And Drug Administration
Summary:
The Food and Drug Administration (FDA) has announced the approval of Vision Blue (trypan blue ophthalmic solution). Vision Blue is the first product approved in the United States for staining the anterior lens capsule during cataract surgery.

The Food and Drug Administration (FDA) has announced the approval of Vision Blue (trypan blue ophthalmic solution). Vision Blue is the first product approved in the United States for staining the anterior lens capsule during cataract surgery.

The use of Vision Blue will enhance the ability of ophthalmologists (eye surgeons) to remove white cataracts, a very advanced mature cataract (typically seen in countries where medical care is not widely available), by allowing the ophthalmologist to see the capsule as it is cut and removed. Clean cuts in the capsule are known to reduce some of the risks associated with the surgical removal of a cataract. Over 1.4 million people have cataract surgery each year in the United States, although only a small portion of these cataracts are mature white cataracts.

A cataract is a clouding of the eye's naturally clear lens. Cataract development is a normal process of aging, but cataracts can also develop from eye injuries, certain diseases, such as diabetes, or medications. The lens focuses light rays on the retina -- the layer of light-sensing cells lining the back of the eye -- to produce a sharp image. When the lens becomes cloudy, light rays cannot pass through it easily, and vision is blurred. Surgery is the only way to remove a cataract. Selective staining of the anterior lens capsule with Vision Blue makes it easier to visualize, manipulate, and remove the cloudy lens through a surgical incision.

The safety and effectiveness of Vision Blue has been established in pediatric patients. No overall differences in safety and effectiveness have been observed between elderly and younger patients.

The adverse reactions from the use of Vision Blue are generally self-limited and of short duration. They include discoloration of intraocular lenses and staining of the posterior lens capsule and the vitreous.

Vision Blue is currently marketed in 30 countries. D.O.R.C. International of the Netherlands is the manufacturer.


Story Source:

The above story is based on materials provided by U.S. Food And Drug Administration. Note: Materials may be edited for content and length.


Cite This Page:

U.S. Food And Drug Administration. "FDA Approves Drug For Use In Cataract Surgery." ScienceDaily. ScienceDaily, 23 December 2004. <www.sciencedaily.com/releases/2004/12/041219133258.htm>.
U.S. Food And Drug Administration. (2004, December 23). FDA Approves Drug For Use In Cataract Surgery. ScienceDaily. Retrieved August 28, 2014 from www.sciencedaily.com/releases/2004/12/041219133258.htm
U.S. Food And Drug Administration. "FDA Approves Drug For Use In Cataract Surgery." ScienceDaily. www.sciencedaily.com/releases/2004/12/041219133258.htm (accessed August 28, 2014).

Share This




More Health & Medicine News

Thursday, August 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Mini Pacemaker Has No Wires

Mini Pacemaker Has No Wires

Ivanhoe (Aug. 27, 2014) Cardiac experts are testing a new experimental device designed to eliminate major surgery and still keep the heart on track. Video provided by Ivanhoe
Powered by NewsLook.com
After Cancer: Rebuilding Breasts With Fat

After Cancer: Rebuilding Breasts With Fat

Ivanhoe (Aug. 27, 2014) More than 269 million women are diagnosed with breast cancer each year. Many of them will need surgery and radiation, but there’s a new simple way to reconstruct tissue using a patient’s own fat. Video provided by Ivanhoe
Powered by NewsLook.com
Blood Clots in Kids

Blood Clots in Kids

Ivanhoe (Aug. 27, 2014) Every year, up to 200,000 Americans die from a blood clot that travels to their lungs. You’ve heard about clots in adults, but new research shows kids can get them too. Video provided by Ivanhoe
Powered by NewsLook.com
Radio Waves Knock out Knee Pain

Radio Waves Knock out Knee Pain

Ivanhoe (Aug. 27, 2014) Doctors have used radio frequency ablation or RFA to reduce neck and back pain for years. But now, that same technique is providing longer-term relief for patients with severe knee pain. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins